Navigation Links
Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
Date:3/31/2009

esign of the trial, including its endpoints, data analysis and conduct. It provides assurance that, if the trial endpoints are met, they will serve as the basis for product approval under a Biologics Licensing Application (BLA). An SPA gives a clear pathway to registration of Urocidin when the trial endpoints are achieved. This indication for MCC received Fast Track designation by the FDA last year. The Company expects to start this trial at such time as it has a marketing partner in place.

About Bladder Cancer

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis and, on appropriate regulatory approvals, might be eligible for multiple treatments with Urocidin.

Non-muscle-invasive bladder cancer is a form of bladder cancer localized in the surface layers of the bladder that has not yet spread into the deeper muscle layer. This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. Urocidin is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder.

About Urocidin(TM)

Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that has a dual mode of action: immune stimulation and direct anticancer activity. Urocidin is formulated for the treatment of bladder cancer, where it is administered by trans-urethral catheter directly into the bladder, coming into contact with immune system cells and bladder cancer cells. Industry Canada's Industrial Technologies Office (for
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. Bioniche Reports Fiscal 2008 Second Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 ... substantially during the five years to 2014. Following a ... thanks to beneficial demographic trends, the expansion of private ... result, IBISWorld estimates that Hearing Aid Clinics industry ... 3.4% to $2.7 billion during the five years to ...
(Date:7/30/2014)... 2014 The global market for hearing ... 2020, growing at an estimated CAGR of 3.2% from ... Grand View Research, Inc. Growing global base of geriatric ... to serve this market as a primary growth driver. ... hearing aid technology and patient awareness levels are expected ...
(Date:7/30/2014)... who have the most common genetic mutation linked to ... overweight or obese people who do not have the ... the Endocrine Society,s Journal of Clinical Endocrinology & ... of adults are obese. Obesity typically results from a ... activity and genetics. In particular, consumption of appetizing foods ...
(Date:7/30/2014)... an Ohio teen who died of a caffeine overdose ... well-tolerated and mass-consumed substance. To help prevent serious health ... scientists are reporting progress toward a rapid, at-home test ... most beverages and even breast milk. Their report appears ... . , Mani Subramanian and colleagues note that caffeine,s ...
(Date:7/30/2014)... McKinney, Texas (PRWEB) July 30, 2014 ... surgical hospital, is proud to announce the launch of ... throat (ENT), and general surgery. The doctors working in ... the needs of infants, children, and adolescents. Dr. Timothy ... Kapadia, Dr. Chad McDuffie, Dr. Neelesh Mehendale, and Dr. ...
Breaking Medicine News(10 mins):Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 2Health News:Victory Medical Center Craig Ranch Debuts Pediatric Care Unit 3
... children with the most common form of childhood cancer ... the cancer cells survive their best efforts and the most ... scientists led by researchers at the University of California, San ... a protein that leukemia cells use to stay alive. Targeting ...
... May 18 (HealthDay News) -- Women who smoke during pregnancy ... a DNA change, a new study suggests. The change, ... researchers argue that the altered genes, which can be passed ... more likely than others to develop certain diseases, such as ...
... antigen) level over several years which had been seen ... recently come under fire as a screening test because it ... A new study, however, shows nearly 70 percent of ... were eventually diagnosed with prostate cancer, according to research from ...
... Minn. -- Mayo Clinic has developed a ... for Lynch syndrome ( http://www.mayoclinic.com/health/lynch-syndrome/DS00669 ), a ... particularly for colorectal cancer. An estimated 3 ... to Lynch syndrome. At least 80 percent ...
... products can be high in harmful saturated fat but not ... of thousands of adults in Costa Rica found that their ... their risk of a heart attack. "Things like milk ... community health graduate student at Brown University and the lead ...
... Jefferson and an international team of collaborators have discovered ... women will respond to anti-estrogen therapy. The research ... Journal of Clinical Oncology . Anti-estrogen drugs, most notably ... breast cancer. However, as many as a third of ...
Cached Medicine News:Health News:UCSF team discovers key to fighting drug-resistant leukemia 2Health News:UCSF team discovers key to fighting drug-resistant leukemia 3Health News:When Pregnant Mom Smokes, Baby's DNA May Change 2Health News:When rising PSA means prostate cancer is in patient's future 2Health News:New Mayo Clinic test targets Lynch syndrome, a risk factor for colon cancer 2Health News:Dairy consumption does not elevate heart-attack risk, study suggests 2Health News:Marker identifies breast cancer patients likely to respond to tamoxifen 2
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... , July 30, 2014 /PRNewswire-iReach/ -- This ... Global and Chinese Heparin sodium (CAS 9041-08-1) & ... the basic information of Heparin sodium (CAS 9041-08-1) ... and manufacturing technology. The report then explores global ... 9041-08-1) & calcium (CAS 37270-89-6) listing their product ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. ... company management will participate in the Jefferies 2014 Boston ... , Massachusetts. The conference will occur on August 6, 2014 ... BioPharma, Inc. PDL BioPharma manages a portfolio ... Queen et al. antibody humanization patents and license agreements ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... May 5, 2011 Ridge Diagnostics, Inc., a ... at the 6th Annual Neurotech Investing and Partnering Conference to ... Hotel on May 9th and 10th.   Ms. ... panel entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, ...
... INDIANAPOLIS, May 5, 2011 Eli Lilly and Company ... an Indianapolis-based nonprofit that supports bold, new education reform, ... What Works campaign. Grow What Works seeks to raise ... working in Indianapolis, enabling them to serve more students ...
Cached Medicine Technology:Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference 2Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 2Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 3Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trust's Grow What Works Campaign 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: